Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Commercialization entities : Gilead sciences, inc. save search
Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors
Published: 2022-11-29 (Crawled : 15:00) - biospace.com/
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: 0.34%
H: 0.43%
C: 0.3%
commercialization therapeutics
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
Published: 2022-06-16 (Crawled : 11:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -3.6%
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: -1.25%
H: 0.82%
C: 0.1%
pharma services commercialization
NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine
Published: 2021-07-12 (Crawled : 15:15) - prnewswire.com
NRXP 5 d | $3.05 1.67% 3.23% 2.3K
|
Manufacturing
|
| O: -2.09%
H: 31.85%
C: -14.37%
URGN | $14.53 1.11% 0.96% 0
|
Health Technology
|
| O: -0.74%
H: 0.74%
C: 0.2%
PYPD | $4.4845 1.35% 4.44% 0
|
Health Technology
|
| O: 4.35%
H: 0.0%
C: -4.5%
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: 0.93%
H: 1.22%
C: -0.23%
GLMD | $0.3614 -0.74% -0.41% 100
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -2.74%
covid israel partnership commercialization vaccine research
China Approves Its First Commercial CAR T-Cell Therapy
Published: 2021-06-23 (Crawled : 15:00) - biospace.com/
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: 0.24%
H: 0.06%
C: -0.83%
china therapy t-cell approval car-t commercialization
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
Published: 2021-06-08 (Crawled : 21:00) - biospace.com/
GH | News 4 | $17.61 1.56% 64K
|
Health Services
|
| O: 1.97%
H: 0.56%
C: -3.4%
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: 0.03%
H: 0.25%
C: 0.1%
health commercialization
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Published: 2021-03-15 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% 0.17% 83K
|
Health Technology
|
| O: 1.21%
H: 1.4%
C: 0.97%
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: 1.28%
H: 1.32%
C: 1.15%
treatment hiv commercialization
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
CZOO | $9.98 100.0% 330K
|
AMST | $3.48 74.0% 21M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.2184 43.4% 36M
|
Consumer Services
ACB | $7.32 16.56% 780K
|
Process Industries
AEYE | $15.42 14.39% 150K
|
Technology Services
BACK | $3.75 13.64% 44K
|
Health Care and Social Assistan...
CGC | $8.835 12.55% 740K
|
Process Industries
BW | News | $1.0002 9.05% 190K
|
Electronic Technology
BILI | $12.525 9.01% 3.5M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.